Furthermore, the reduction of glucose and circulating IGF enhance the efficacy of cycline kinase inhibitors/hormone therapy combination and PI3 kinase inhibitors against ER-positive and triple-negative tumors, respectively, preventing drug resistance in ER+ breast cancers [244] and completely eradicating triple-negative breast tumors [243]. This evidence concerns the gene IGF1 and breast carcinoma.